加载中
NASDAQHealthcareDrug Manufacturers - Specialty & Generic
最新数据
US$22.09
−US$0.02 · -0.09%
Collegium Pharmaceutical, Inc. (COLL) is a specialized pharmaceutical firm dedicated to the development and marketing of medications for pain management. Its diverse product lineup features significant therapies aimed at addressing various pain conditions. A prominent offering is Xtampza ER, an extended-release, oral formulation of oxycodone, specifically engineered with properties to deter abuse. This particular drug is prescribed for patients experiencing severe, persistent pain that necessitates daily, continuous, long-term opioid therapy. The company's portfolio also encompasses Nucynta ER and Nucynta IR, which are extended-release and immediate-release versions of tapentadol, respectively. Founded in 2002, the enterprise initially operated under the name Collegium Pharmaceuticals, Inc., before officially adopting its current identity as Collegium Pharmaceutical, Inc. in October 2003. The company's corporate headquarters are situated in Stoughton, Massachusetts.
前收盘价
US$22.09
−US$0.02 · -0.09%
盘中时间采用ET。市场数据可能有所延迟。
Collegium Pharmaceutical, Inc. (COLL) is a specialized pharmaceutical firm dedicated to the development and marketing of medications for pain management. Its diverse product lineup features significant therapies aimed at addressing various pain conditions. A prominent offering is Xtampza ER, an extended-release, oral formulation of oxycodone, specifically engineered with properties to deter abuse. This particular drug is prescribed for patients experiencing severe, persistent pain that necessitates daily, continuous, long-term opioid therapy. The company's portfolio also encompasses Nucynta ER and Nucynta IR, which are extended-release and immediate-release versions of tapentadol, respectively. Founded in 2002, the enterprise initially operated under the name Collegium Pharmaceuticals, Inc., before officially adopting its current identity as Collegium Pharmaceutical, Inc. in October 2003. The company's corporate headquarters are situated in Stoughton, Massachusetts.
日内区间
当前US$22.09
52周区间
当前US$22.09
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
买入
估值
98
深度低估
情绪
60
多空交织
风险
44
风险偏高
动量
40
动能减弱
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Collegium Pharmaceutical, Inc. (COLL) is a specialized pharmaceutical firm dedicated to the development and marketing of medications for pain management. Its diverse product lineup features significant therapies aimed at addressing various pain conditions. A prominent offering is Xtampza ER, an extended-release, oral formulation of oxycodone, specifically engineered with properties to deter abuse. This particular drug is prescribed for patients experiencing severe, persistent pain that necessitates daily, continuous, long-term opioid therapy. The company's portfolio also encompasses Nucynta ER and Nucynta IR, which are extended-release and immediate-release versions of tapentadol, respectively. Founded in 2002, the enterprise initially operated under the name Collegium Pharmaceuticals, Inc., before officially adopting its current identity as Collegium Pharmaceutical, Inc. in October 2003. The company's corporate headquarters are situated in Stoughton, Massachusetts.
日内区间
当前US$22.09
52周区间
当前US$22.09
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 7.81亿 USD | 6.31亿 USD | 5.67亿 USD | 4.64亿 USD | 2.77亿 USD |
| 销货成本 | 3.17亿 USD | 2.54亿 USD | 2.41亿 USD | 2.54亿 USD | 1.26亿 USD |
| 毛利 | 4.63亿 USD | 3.77亿 USD | 3.26亿 USD | 2.09亿 USD | 1.51亿 USD |
| 研究与开发 | — | — | — | 398.3万 USD | 945.1万 USD |
| 销售、一般及管理费用 | 2.76亿 USD | 1.83亿 USD | 1.59亿 USD | 1.72亿 USD | 1.19亿 USD |
| 营业费用 | 2.76亿 USD | 2.07亿 USD | 1.59亿 USD | 1.76亿 USD | 1.33亿 USD |
| 利息收入 | 1128.9万 USD | 1397.6万 USD | 1561.5万 USD | 104.7万 USD | 1.2万 USD |
| 利息支出 | 8231.2万 USD | 7397.4万 USD | 8333.9万 USD | 6321.3万 USD | 2101.4万 USD |
| 折旧和摊销 | 2.26亿 USD | 1.69亿 USD | 1.49亿 USD | 1.39亿 USD | 6891.7万 USD |
| 营业利润 | 1.87亿 USD | 1.7亿 USD | 1.67亿 USD | 3331.9万 USD | 1762.8万 USD |
| 净利润 | 6287万 USD | 6919万 USD | 4815.5万 USD | −2500.2万 USD | 7151.7万 USD |
公司数据更新于 2026年10月11日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$48.00
上涨空间 117.29%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI2406.75万0.00%2.3万亿 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM1907.36万0.02%787.4亿 USD0.19%US$278.94+0.49%
Invesco Pharmaceuticals ETFPJP1418.7万2.59%5.48亿 USD0.58%US$122.88+1.56%
Avantis U.S. Small Cap Value ETFAVUV1050.55万0.03%308.51亿 USD0.25%US$119.64-0.41%
Invesco Biotechnology & Genome ETFPBE941.46万2.23%4.22亿 USD0.59%US$97.065+2.98%
Vanguard Extended Market ETFVXF925.14万0.01%954亿 USD0.05%US$235+0.80%
State Street SPDR S&P Pharmaceuticals ETFXPH866.93万1.88%4.62亿 USD0.35%US$64.65+1.60%
Pacer US Small Cap Cash Cows ETFCALF680.89万0.19%35.87亿 USD0.59%US$54.66-0.16%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMInvesco Pharmaceuticals ETFPJPAvantis U.S. Small Cap Value ETFAVUVInvesco Biotechnology & Genome ETFPBEVanguard Extended Market ETFVXFState Street SPDR S&P Pharmaceuticals ETFXPHPacer US Small Cap Cash Cows ETFCALFAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
